{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:20:27Z","timestamp":1794428427263,"version":"4.9.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04219-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:14:54Z","timestamp":1770297294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication"],"prefix":"10.1186","volume":"26","author":[{"given":"Aiyun","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-591X","authenticated-orcid":false,"given":"Farzaneh","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"1","key":"4219_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/hematology.2020002547","volume":"2020","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematol Am Soc Hematol Educ Program. 2020;2020(1):570\u20138. https:\/\/doi.org\/10.1182\/hematology.2020002547.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"4219_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10(1):318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1.","journal-title":"Cell Death Discov"},{"issue":"1","key":"4219_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T. The clinical landscape of CAR NK cells. Exp Hematol Oncol. 2025;14(1):46. https:\/\/doi.org\/10.1186\/s40164-025-00633-8.","journal-title":"Exp Hematol Oncol"},{"key":"4219_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biom14081035","author":"W Li","year":"2024","unstructured":"Li W, Wang X, Zhang X, Aziz AUR, Wang D. CAR-NK cell therapy: a transformative approach to overcoming oncological challenges. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14081035.","journal-title":"Biomolecules"},{"issue":"4","key":"4219_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101121","volume":"11","author":"M Khoshandam","year":"2024","unstructured":"Khoshandam M, Soltaninejad H, Hamidieh AA, Hosseinkhani S. CRISPR, CAR-T, and NK: current applications and future perspectives. Genes & Diseases. 2024;11(4):101121. https:\/\/doi.org\/10.1016\/j.gendis.2023.101121.","journal-title":"Genes & Diseases"},{"issue":"11","key":"4219_CR6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederst\u00e4dt","year":"2025","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineered natural killer cells for cancer therapy. Cancer Cell. 2025;43(11):1987\u20132013. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.013.","journal-title":"Cancer Cell"},{"issue":"6","key":"4219_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"key":"4219_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","author":"BH Goldenson","year":"2022","unstructured":"Goldenson BH, Hor P, Kaufman DS. Ipsc-derived natural killer cell therapies - expansion and targeting. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.841107.","journal-title":"Front Immunol"},{"issue":"7","key":"4219_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70045","volume":"14","author":"J Sun","year":"2025","unstructured":"Sun J, Elliott M, Souza-Fonseca-Guimaraes F. Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy. Clinical & translational immunology. 2025;14(7):e70045. https:\/\/doi.org\/10.1002\/cti2.70045.","journal-title":"Clinical & translational immunology"},{"key":"4219_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262211224","author":"A Bastrich","year":"2025","unstructured":"Bastrich A, Vinogradova K, Mokrousova D, Efremova A, Makhnach O, Goldshtein D. State of the art of CAR-NK cell therapy in multiple myeloma: a comprehensive review of cell sources and target antigens. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms262211224.","journal-title":"Int J Mol Sci"},{"issue":"10473","key":"4219_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405(10473):127\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)02462-0.","journal-title":"Lancet"},{"issue":"5","key":"4219_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann H. The NK-92 cell line\u201430 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25(5):451\u20137. https:\/\/doi.org\/10.1016\/j.jcyt.2022.12.003.","journal-title":"Cytotherapy"},{"issue":"12","key":"4219_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121968","volume":"17","author":"H Klingemann","year":"2025","unstructured":"Klingemann H. The natural killer cell line NK-92 and its genetic variants: impact on NK cell research and cancer immunotherapy. Cancers. 2025;17(12):1968.","journal-title":"Cancers"},{"issue":"1","key":"4219_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911. https:\/\/doi.org\/10.1038\/s41467-018-04252-2.","journal-title":"Nat Commun"},{"key":"4219_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.omtm.2023.03.006","volume":"29","author":"DH Jo","year":"2023","unstructured":"Jo DH, Kaczmarek S, Shin O, Wang L, Cowan J, McComb S, et al. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Mol Ther Methods Clin Dev. 2023;29:173\u201384. https:\/\/doi.org\/10.1016\/j.omtm.2023.03.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4219_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2023.1203864","volume":"5","author":"A Hendel","year":"2023","unstructured":"Hendel A, Bak RO. Editorial: CRISPR and beyond: cutting-edge technologies for gene correction in therapeutic applications. Front Genome Ed. 2023;5:1203864. https:\/\/doi.org\/10.3389\/fgeed.2023.1203864.","journal-title":"Front Genome Ed"},{"key":"4219_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600411","author":"C Hu","year":"2025","unstructured":"Hu C, Lai W, Tian B, Xu X, Xie S, Zhong W, et al. Application and prospects of genetic engineering in CAR-NK cell therapy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1600411.","journal-title":"Front Immunol"},{"key":"4219_CR18","doi-asserted-by":"publisher","unstructured":"Guedan S, Calderon H, Posey AD Jr., Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2018.12.009.","DOI":"10.1016\/j.omtm.2018.12.009"},{"issue":"1","key":"4219_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46\u201362. https:\/\/doi.org\/10.1016\/j.cell.2020.03.001.","journal-title":"Cell"},{"issue":"7","key":"4219_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824\u201344. https:\/\/doi.org\/10.1038\/s41587-020-0561-9.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"4219_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927\u201330. https:\/\/doi.org\/10.1038\/s41591-018-0049-z.","journal-title":"Nat Med"},{"issue":"8","key":"4219_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371. https:\/\/doi.org\/10.1038\/nbt.4192.","journal-title":"Nat Biotechnol"},{"issue":"6448","key":"4219_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1126\/science.aax9181","volume":"365","author":"J Strecker","year":"2019","unstructured":"Strecker J, Ladha A, Gardner Z, Schmid-Burgk JL, Makarova KS, Koonin EV, et al. RNA-guided DNA insertion with CRISPR-associated transposases. Science. 2019;365(6448):48\u201353. https:\/\/doi.org\/10.1126\/science.aax9181.","journal-title":"Science"},{"issue":"7785","key":"4219_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357. https:\/\/doi.org\/10.1038\/s41586-019-1711-4.","journal-title":"Nature"},{"issue":"7603","key":"4219_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420\u20134. https:\/\/doi.org\/10.1038\/nature17946.","journal-title":"Nature"},{"issue":"1","key":"4219_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.13031","volume":"305","author":"CM Lau","year":"2022","unstructured":"Lau CM, Wiedemann GM, Sun JC. Epigenetic regulation of natural killer cell memory. Immunol Rev. 2022;305(1):90\u2013110. https:\/\/doi.org\/10.1111\/imr.13031.","journal-title":"Immunol Rev"},{"issue":"2","key":"4219_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/icb.2010.78","volume":"89","author":"HJ Pegram","year":"2011","unstructured":"Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216\u201324. https:\/\/doi.org\/10.1038\/icb.2010.78.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"4219_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1084\/jem.192.7.1059","volume":"192","author":"J Wu","year":"2000","unstructured":"Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med. 2000;192(7):1059\u201368. https:\/\/doi.org\/10.1084\/jem.192.7.1059.","journal-title":"J Exp Med"},{"issue":"1","key":"4219_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther. 2024;9(1):302. https:\/\/doi.org\/10.1038\/s41392-024-02005-w.","journal-title":"Signal Transduct Target Ther"},{"key":"4219_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081955","author":"M Khalil","year":"2021","unstructured":"Khalil M, Wang D, Hashemi E, Terhune SS, Malarkannan S. Implications of a \u201cThird signal\u201d in NK cells. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081955.","journal-title":"Cells"},{"key":"4219_CR31","doi-asserted-by":"publisher","DOI":"10.70389\/PJBS.100002","author":"W Mary Christine","year":"2025","unstructured":"Mary Christine W. Gene editing: CRISPR and beyond. Premier J Biomedical Sci. 2025. https:\/\/doi.org\/10.70389\/PJBS.100002.","journal-title":"Premier J Biomedical Sci"},{"key":"4219_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104912","volume":"214","author":"F Zhang","year":"2025","unstructured":"Zhang F, Samarkhazan HS, Pooraskari Z, Bayani A. Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy. Crit Rev Oncol Hematol. 2025;104912. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104912.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4219_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, Servatian N, Al-Athari AJH, Khafaja ESM, Rahmani Seraji H, Soleimani Samarkhazan H. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Exp Med. 2025;25(1):230. https:\/\/doi.org\/10.1007\/s10238-025-01783-z.","journal-title":"Clin Exp Med"},{"key":"4219_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070935","author":"H Kim","year":"2025","unstructured":"Kim H. Overcoming immune barriers in allogeneic CAR-NK therapy: from multiplex gene editing to AI-driven precision design. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15070935.","journal-title":"Biomolecules"},{"key":"4219_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142397","author":"B Amoozgar","year":"2025","unstructured":"Amoozgar B, Bangolo A, Mansour C, Elias D, Mohamed A, Thor DC, et al. Engineering innate immunity: recent advances and future directions for CAR-NK and CAR-macrophage therapies in solid tumors. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17142397.","journal-title":"Cancers"},{"issue":"9","key":"4219_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04106-z","volume":"74","author":"S Li","year":"2025","unstructured":"Li S, Jing J, Chen Y, Chi E, Wang B, Xie Z, et al. Precision sniper for solid tumors: CAR-NK cell therapy. Cancer Immunol Immunother. 2025;74(9):275. https:\/\/doi.org\/10.1007\/s00262-025-04106-z.","journal-title":"Cancer Immunol Immunother"},{"key":"4219_CR37","doi-asserted-by":"publisher","unstructured":"Clubb JD, Gao TA, Chen YY. Synthetic biology in the engineering of CAR-T and CAR-NK cell therapies: facts and hopes. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2023;29(8):1390\u2013402. https:\/\/doi.org\/10.1158\/1078\u2009\u2212\u20090432.ccr-22-1491.","DOI":"10.1158\/1078\u2009\u2212\u20090432.ccr-22-1491"},{"issue":"6","key":"4219_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"issue":"7756","key":"4219_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","volume":"569","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald J, Zhou R, Garcia SP, Iyer S, Lareau CA, Aryee MJ, et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature. 2019;569(7756):433\u20137. https:\/\/doi.org\/10.1038\/s41586-019-1161-z.","journal-title":"Nature"},{"issue":"6","key":"4219_CR40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41592-023-01859-2","volume":"20","author":"S-Q Liang","year":"2023","unstructured":"Liang S-Q, Liu P, Ponnienselvan K, Suresh S, Chen Z, Kramme C, et al. Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nat Methods. 2023;20(6):898\u2013907. https:\/\/doi.org\/10.1038\/s41592-023-01859-2.","journal-title":"Nat Methods"},{"key":"4219_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108198","volume":"171","author":"H Gong","year":"2024","unstructured":"Gong H, Liu Z, Yuan C, Luo Y, Chen Y, Zhang J, et al. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Comput Biol Med. 2024;171:108198. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.108198.","journal-title":"Comput Biol Med"},{"issue":"811","key":"4219_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn2601","volume":"17","author":"S Radtke","year":"2025","unstructured":"Radtke S, Fields E, Swing K, Kanestrom G, Yen JS, Pande D, et al. Engraftment and persistence of HBB base-edited hematopoietic stem cells in nonhuman primates. Sci Transl Med. 2025;17(811):eadn2601. https:\/\/doi.org\/10.1126\/scitranslmed.adn2601.","journal-title":"Sci Transl Med"},{"issue":"3","key":"4219_CR43","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384. https:\/\/doi.org\/10.1038\/s41591-023-02785-8.","journal-title":"Nat Med"},{"issue":"14","key":"4219_CR44","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a Mesothelin-Specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0351.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4219_CR45","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/0008-5472.can-17-0799","volume":"77","author":"F Cichocki","year":"2017","unstructured":"Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res. 2017;77(20):5664\u201375. https:\/\/doi.org\/10.1158\/0008-5472.can-17-0799.","journal-title":"Cancer Res"},{"key":"4219_CR46","doi-asserted-by":"crossref","unstructured":"Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T\u00a0cell transition in CAR T\u00a0cell dysfunction. Cell. 2021;184(25):6081\u2009\u2013\u2009100.e26.10.1016\/j.cell.2021.11.016.","DOI":"10.1016\/j.cell.2021.11.016"},{"issue":"1","key":"4219_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Noormohamadi H, Shafiei FS, Taghinejad Z, Maleknia M, Raoufi A, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Exp Med. 2025;25(1):215. https:\/\/doi.org\/10.1007\/s10238-025-01764-2.","journal-title":"Clin Exp Med"},{"issue":"1","key":"4219_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Shafiei FS, Taghinejad Z, Maleknia M, Noormohamadi H, Raoufi A, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med. 2025;25(1):240. https:\/\/doi.org\/10.1007\/s10238-025-01795-9.","journal-title":"Clin Exp Med"},{"key":"4219_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","journal-title":"EBioMedicine"},{"issue":"7","key":"4219_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1244","volume":"13","author":"EM Bressler","year":"2023","unstructured":"Bressler EM, Adams S, Liu R, Colson YL, Wong WW, Grinstaff MW. Boolean logic in synthetic biology and biomaterials: towards living materials in mammalian cell therapeutics. Clin Transl Med. 2023;13(7):e1244. https:\/\/doi.org\/10.1002\/ctm2.1244.","journal-title":"Clin Transl Med"},{"key":"4219_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/jci162593","author":"J Appelbaum","year":"2024","unstructured":"Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G, et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/jci162593.","journal-title":"J Clin Invest"},{"key":"4219_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2023.04.005","volume":"29","author":"D Lain\u0161\u010dek","year":"2023","unstructured":"Lain\u0161\u010dek D, Golob-Urbanc A, Mikoli\u010d V, Pantovi\u0107-\u017dalig J, Malen\u0161ek \u0160, Jerala R. Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor. Mol Ther Oncolytics. 2023;29:77\u201390. https:\/\/doi.org\/10.1016\/j.omto.2023.04.005.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"4219_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.can-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Chen J, Li W, Xu Y, Shan J, Hong J, et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 2024;84(1):84\u2013100. https:\/\/doi.org\/10.1158\/0008-5472.can-23-1038.","journal-title":"Cancer Res"},{"issue":"4","key":"4219_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100244","volume":"2","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Krenciute G. Hypoxia-inducible CAR expression: an answer to the on-target\/off-tumor dilemma? Cell Rep Med. 2021;2(4):100244. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100244.","journal-title":"Cell Rep Med"},{"issue":"7","key":"4219_CR55","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s12276-025-01463-8","volume":"57","author":"J Lee","year":"2025","unstructured":"Lee J, Kweon J, Kim Y. Emerging trends in prime editing for precision genome editing. Exp Mol Med. 2025;57(7):1381\u201391. https:\/\/doi.org\/10.1038\/s12276-025-01463-8.","journal-title":"Exp Mol Med"},{"key":"4219_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157.","journal-title":"Front Bioeng Biotechnol"},{"key":"4219_CR57","unstructured":"Chemistry M, Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), editors. Food and Drug Administration. 2020."},{"issue":"9","key":"4219_CR58","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","volume":"28","author":"YK Jeong","year":"2020","unstructured":"Jeong YK, Song B, Bae S. Current status and challenges of DNA base editing tools. Mol Ther. 2020;28(9):1938\u201352. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.021.","journal-title":"Mol Ther"},{"key":"4219_CR59","doi-asserted-by":"crossref","unstructured":"Lazzarotto CR, Katta V, Li Y, Manquen G, Wood RK, Chyr J et al. Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE. Nature Biotechnology. 2026.10.1038\/s41587-025-02948-7.","DOI":"10.1038\/s41587-025-02948-7"},{"issue":"8087","key":"4219_CR60","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41586-025-09537-3","volume":"646","author":"VP Chauhan","year":"2025","unstructured":"Chauhan VP, Sharp PA, Langer R. Engineered prime editors with minimal genomic errors. Nature. 2025;646(8087):1254\u201360. https:\/\/doi.org\/10.1038\/s41586-025-09537-3.","journal-title":"Nature"},{"issue":"9","key":"4219_CR61","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41587-019-0236-6","volume":"37","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald J, Zhou R, Iyer S, Lareau CA, Garcia SP, Aryee MJ, et al. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol. 2019;37(9):1041\u20138. https:\/\/doi.org\/10.1038\/s41587-019-0236-6.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4219_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41587-020-0407-5","volume":"38","author":"T Gilpatrick","year":"2020","unstructured":"Gilpatrick T, Lee I, Graham JE, Raimondeau E, Bowen R, Heron A, et al. Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020;38(4):433\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0407-5.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4219_CR63","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/bit.28382","volume":"120","author":"K Leitner","year":"2023","unstructured":"Leitner K, Motheramgari K, Borth N, Marx N. Nanopore Cas9-targeted sequencing enables accurate and simultaneous identification of transgene integration sites, their structure and epigenetic status in recombinant Chinese hamster ovary cells. Biotechnol Bioeng. 2023;120(9):2403\u201318. https:\/\/doi.org\/10.1002\/bit.28382.","journal-title":"Biotechnol Bioeng"},{"issue":"18","key":"4219_CR64","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1106152.","journal-title":"N Engl J Med"},{"issue":"6","key":"4219_CR65","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.ymthe.2024.12.057","volume":"33","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh H, Wang L-S, Mirzaei H, Amoozgar Z, Tian L, Yu J. Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol Ther. 2025;33(6):2406\u201325. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.057.","journal-title":"Mol Ther"},{"issue":"1","key":"4219_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18(1):62. https:\/\/doi.org\/10.1186\/s13045-025-01701-6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4219_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/in9.0000000000000020","volume":"5","author":"H Sohn","year":"2023","unstructured":"Sohn H, Cooper MA. Metabolic regulation of NK cell function: implications for immunotherapy. Immunometabolism (Cobham, Surrey). 2023;5(1):e00020. https:\/\/doi.org\/10.1097\/in9.0000000000000020.","journal-title":"Immunometabolism (Cobham, Surrey)"},{"key":"4219_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00202","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Guan D, Wang S, Chai LYA, Xu S, Lam KP. Glycolysis and oxidative phosphorylation play critical roles in natural killer cell receptor-mediated natural killer cell functions. Front Immunol. 2020;11:202. https:\/\/doi.org\/10.3389\/fimmu.2020.00202.","journal-title":"Front Immunol"},{"issue":"11","key":"4219_CR69","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-022-01327-7","volume":"23","author":"T R\u00fcckert","year":"2022","unstructured":"R\u00fcckert T, Lareau CA, Mashreghi M-F, Ludwig LS, Romagnani C. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat Immunol. 2022;23(11):1551\u201363. https:\/\/doi.org\/10.1038\/s41590-022-01327-7.","journal-title":"Nat Immunol"},{"issue":"2","key":"4219_CR70","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3343\/alm.2024.0380","volume":"45","author":"JD Park","year":"2025","unstructured":"Park JD, Shin HE, An YS, Jang HJ, Park J, Kim S-N, et al. Advancing natural killer cell therapy: genetic engineering strategies for enhanced cancer immunotherapy. Ann Lab Med. 2025;45(2):146\u201359. https:\/\/doi.org\/10.3343\/alm.2024.0380.","journal-title":"Ann Lab Med"},{"issue":"3","key":"4219_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3(3):100543. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100543.","journal-title":"Cell Rep Med"},{"key":"4219_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1651526","volume":"16","author":"R Kumar","year":"2025","unstructured":"Kumar R, Veillard IE, Xu M, Al-Alem L, Rueda BR, Yeku OO. CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer. Front Pharmacol. 2025;16:1651526. https:\/\/doi.org\/10.3389\/fphar.2025.1651526.","journal-title":"Front Pharmacol"},{"issue":"13","key":"4219_CR73","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/cm9.0000000000003346","volume":"138","author":"MB Khawar","year":"2025","unstructured":"Khawar MB, Afzal A, Dong S, Si Y, Sun H. Engineering and targeting potential of CAR NK cells in colorectal cancer. Chin Med J. 2025;138(13):1529\u201339. https:\/\/doi.org\/10.1097\/cm9.0000000000003346.","journal-title":"Chin Med J"},{"issue":"1","key":"4219_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6782046","volume":"2020","author":"B He","year":"2020","unstructured":"He B, Xu J, Tian Y, Liao B, Lang J, Lin H, et al. Gene coexpression network and module analysis across 52 human tissues. Biomed Res Int. 2020;2020(1):6782046. https:\/\/doi.org\/10.1155\/2020\/6782046.","journal-title":"Biomed Res Int"},{"key":"4219_CR75","unstructured":"Fox GC. Regulation and function of integrin \u03b23 in Bone-Metastatic breast cancer cells in the therapeutic setting. Division of Biology and Biomedical Sciences Molecular Cell Biology; 2022."},{"key":"4219_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1052192","volume":"12","author":"S Kim","year":"2022","unstructured":"Kim S, Wan Z, Jeon JS, Kamm RD. Microfluidic vascular models of tumor cell extravasation. Front Oncol. 2022;12:1052192. https:\/\/doi.org\/10.3389\/fonc.2022.1052192.","journal-title":"Front Oncol"},{"key":"4219_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216103","volume":"558","author":"R Zhang","year":"2023","unstructured":"Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia. Cancer Lett. 2023;558:216103. https:\/\/doi.org\/10.1016\/j.canlet.2023.216103.","journal-title":"Cancer Lett"},{"key":"4219_CR78","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jare.2024.08.029","volume":"73","author":"L Xu","year":"2025","unstructured":"Xu L, Ma W, Huo X, Luo J, Li R, Zhu X, et al. New insights into the function and mechanisms of piRNA PMLCPIR in promoting PM2.5-induced lung cancer. J Adv Res. 2025;73:659\u201370. https:\/\/doi.org\/10.1016\/j.jare.2024.08.029.","journal-title":"J Adv Res"},{"issue":"4","key":"4219_CR79","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell. 2016;164(4):780\u201391. https:\/\/doi.org\/10.1016\/j.cell.2016.01.012.","journal-title":"Cell"},{"issue":"11","key":"4219_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small (Weinheim an der Bergstrasse, Germany). 2024;20(11):e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"4219_CR81","unstructured":"Phase A, Open-Label I. Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed\/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04245722"},{"issue":"10473","key":"4219_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet (London, England). 2025;405(10473):127\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(24)02462-0.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"4219_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102515","volume":"20","author":"Y Fang","year":"2025","unstructured":"Fang Y, Chen Y, Li Y-R. Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem Cell Rep. 2025;20(7):102515. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102515.","journal-title":"Stem Cell Rep"},{"key":"4219_CR84","unstructured":"Phase A, IIa Open I, Label, Non-Randomized. Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G\/GEJ) Aenocarcinoma [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05207722"},{"key":"4219_CR85","doi-asserted-by":"crossref","unstructured":"Gutierrez M, Sigal D, Berth K, Kuehn A, Colerangle J, Koppisetti S et al. A phase I\/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma. Journal of Clinical Oncology. 2023;41(4_suppl):TPS478-TPS.10.1200\/JCO.2023.41.4_suppl.TPS478.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS478"},{"key":"4219_CR86","unstructured":"ICH guideline S2 (R1). On genotoxicity testing and data interpretation for pharmaceuticals intended for human use. European Medicines Agency; 2012."},{"key":"4219_CR87","unstructured":"Guideline on quality., non-clinical and clinical aspects of medicinal products containing genetically modified cells. European Medicines Agency; 2021."},{"key":"4219_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.673022","volume":"3","author":"A Atkins","year":"2021","unstructured":"Atkins A, Chung CH, Allen AG, Dampier W, Gurrola TE, Sariyer IK, et al. Off-target analysis in gene editing and applications for clinical translation of CRISPR\/Cas9 in HIV-1 therapy. Front Genome Ed. 2021;3:673022. https:\/\/doi.org\/10.3389\/fgeed.2021.673022.","journal-title":"Front Genome Ed"},{"key":"4219_CR89","doi-asserted-by":"crossref","unstructured":"Mann CJ, Giblin J, Braun M, Schmid F, S\u00f8rensen MR, Caferra P, et al. Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products. Cell Rep Med. 2025;6(12):102422.","DOI":"10.1016\/j.xcrm.2025.102422"},{"key":"4219_CR90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","volume":"10","author":"VL Simhadri","year":"2018","unstructured":"Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev. 2018;10:105\u201312. https:\/\/doi.org\/10.1016\/j.omtm.2018.06.006.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"4219_CR91","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","volume":"8","author":"S Guo","year":"2024","unstructured":"Guo S, Lei W, Jin X, Liu H, Wang JQ, Deng W, et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv. 2024;8(11):2635\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2023012202.","journal-title":"Blood Adv"},{"issue":"11","key":"4219_CR92","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","volume":"38","author":"CR Lazzarotto","year":"2020","unstructured":"Lazzarotto CR, Malinin NL, Li Y, Zhang R, Yang Y, Lee G, et al. CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity. Nat Biotechnol. 2020;38(11):1317\u201327. https:\/\/doi.org\/10.1038\/s41587-020-0555-7.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4219_CR93","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","volume":"14","author":"SQ Tsai","year":"2017","unstructured":"Tsai SQ, Nguyen NT, Malagon-Lopez J, Topkar VV, Aryee MJ, Joung JK. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods. 2017;14(6):607\u201314. https:\/\/doi.org\/10.1038\/nmeth.4278.","journal-title":"Nat Methods"},{"key":"4219_CR94","doi-asserted-by":"crossref","unstructured":"Lazzarotto CR, Katta V, Li Y, Urbina E, Lee G, Tsai SQ. CHANGE-seq-BE enables simultaneously sensitive and unbiased in vitro profiling of base editor genome-wide activity. bioRxiv: the preprint server for biology. 2024.10.1101\/2024.03.28.586621.","DOI":"10.1101\/2024.03.28.586621"},{"key":"4219_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1708724","volume":"13","author":"K Kochergin-Nikitsky","year":"2025","unstructured":"Kochergin-Nikitsky K, Lavrov A, Smirnikhina S. Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors. Front Bioeng Biotechnol. 2025;13:1708724. https:\/\/doi.org\/10.3389\/fbioe.2025.1708724.","journal-title":"Front Bioeng Biotechnol"},{"key":"4219_CR96","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.omtm.2022.01.009","volume":"24","author":"J Ryu","year":"2022","unstructured":"Ryu J, Chan W, Wettengel JM, Hanna CB, Burwitz BJ, Hennebold JD, et al. Rapid, accurate mapping of transgene integration in viable rhesus macaque embryos using enhanced-specificity tagmentation-assisted PCR. Mol Therapy - Methods Clin Dev. 2022;24:241\u201354. https:\/\/doi.org\/10.1016\/j.omtm.2022.01.009.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"4219_CR97","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-3753-0_9","volume":"1448","author":"W Wang","year":"2016","unstructured":"Wang W, Bartholomae CC, Gabriel R, Deichmann A, Schmidt M. The LAM-PCR method to sequence LV integration sites. Methods in molecular biology (Clifton, NJ). 2016;1448:107\u201320. https:\/\/doi.org\/10.1007\/978-1-4939-3753-0_9.","journal-title":"Methods in molecular biology (Clifton, NJ)"},{"key":"4219_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702636","author":"D Bode","year":"2021","unstructured":"Bode D, Cull AH, Rubio-Lara JA, Kent DG. Exploiting single-cell tools in gene and cell therapy. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.702636.","journal-title":"Front Immunol"},{"issue":"5","key":"4219_CR99","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.hoc.2017.05.002","volume":"31","author":"CT Lux","year":"2017","unstructured":"Lux CT, Scharenberg AM. Therapeutic gene editing safety and specificity. Hematol Oncol Clin North Am. 2017;31(5):787\u201395. https:\/\/doi.org\/10.1016\/j.hoc.2017.05.002.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"4219_CR100","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/biomedicines11041107","volume":"11","author":"K Pierzynowska","year":"2023","unstructured":"Pierzynowska K, Gaffke L, Zaucha JM, W\u0119grzyn G. Transcriptomic approaches in studies on and applications of chimeric antigen receptor T cells. Biomedicines [Internet]. 2023;11(4):1107. p.].","journal-title":"Biomedicines [Internet]"},{"issue":"2","key":"4219_CR101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0326-x.","journal-title":"Nat Med"},{"key":"4219_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1138596","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics\u2014critical considerations for clinical translation. Front Bioeng Biotechnol. 2023. https:\/\/doi.org\/10.3389\/fbioe.2023.1138596.","journal-title":"Front Bioeng Biotechnol"},{"issue":"n\/a","key":"4219_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/nano.70039","volume":"n\/a","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Khaksari MN, Mirzazadeh A, Siavashi M, Pilehvari N, Mohammadi MH. Nanosensors in leukemia management: pioneering real-time biomarker detection for precision oncology. Nano Select. 2025;n\/a(n\/a):e70039. https:\/\/doi.org\/10.1002\/nano.70039.","journal-title":"Nano Select"},{"issue":"8073","key":"4219_CR104","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","volume":"643","author":"H Rafei","year":"2025","unstructured":"Rafei H, Basar R, Acharya S, Hsu Y-S, Liu P, Zhang D, et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature. 2025;643(8073):1076\u201386. https:\/\/doi.org\/10.1038\/s41586-025-09087-8.","journal-title":"Nature"},{"issue":"11","key":"4219_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102282","volume":"6","author":"A Kumar","year":"2025","unstructured":"Kumar A, Fischer C, Cichocki F, Miller JS. Multiplexed iPSC platform for advanced NK cell immunotherapies. Cell Rep Med. 2025;102282. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102282.","journal-title":"Cell Rep Med"},{"key":"4219_CR106","unstructured":"Considerations for the Development. Of chimeric antigen receptor (CAR) T cell products. FDA; 2024."},{"key":"4219_CR107","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Matosevic S. Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy. Molecular Therapy - Oncolytics. 2022;27:224\u201338. https:\/\/doi.org\/10.1016\/j.omto.2022.10.011.","journal-title":"Molecular Therapy - Oncolytics"},{"key":"4219_CR108","unstructured":"Cellular. Gene therapy guidances. FDA; 2025."},{"key":"4219_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071482","author":"I Toma","year":"2022","unstructured":"Toma I, Porfire AS, Tefas LR, Berindan-Neagoe I, Tomu\u021b\u0103 I. A quality by design approach in pharmaceutical development of non-viral vectors with a focus on miRNA. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14071482.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4219_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, Nouri S, Hussen A, Bayani A, Khaksari MN, Soleimani Samarkhazan H. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166. https:\/\/doi.org\/10.1007\/s10238-025-01686-z.","journal-title":"Clin Exp Med"},{"issue":"1","key":"4219_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55094-0","volume":"15","author":"W He","year":"2024","unstructured":"He W, Zhu J, Feng Y, Liang F, You K, Chai H, et al. Neuromorphic-enabled video-activated cell sorting. Nat Commun. 2024;15(1):10792. https:\/\/doi.org\/10.1038\/s41467-024-55094-0.","journal-title":"Nat Commun"},{"key":"4219_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, van Diest E, Murphy DE, Ashoti A, Evers MJW, Narayanavari SA, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"key":"4219_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713364","author":"V Golubovskaya","year":"2023","unstructured":"Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713364.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4219_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451008","volume":"54","author":"EH Kim","year":"2024","unstructured":"Kim EH, Teerdhala SV, Padilla MS, Joseph RA, Li JJ, Haley RM, et al. Lipid nanoparticle-mediated RNA delivery for immune cell modulation. Eur J Immunol. 2024;54(12):e2451008. https:\/\/doi.org\/10.1002\/eji.202451008.","journal-title":"Eur J Immunol"},{"issue":"6","key":"4219_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70447","volume":"97","author":"L Yin","year":"2025","unstructured":"Yin L, He H, Zhang H, Shang Y, Fu C, Wu S, et al. Revolution of AAV in drug discovery: from delivery system to clinical application. J Med Virol. 2025;97(6):e70447. https:\/\/doi.org\/10.1002\/jmv.70447.","journal-title":"J Med Virol"},{"key":"4219_CR116","doi-asserted-by":"crossref","unstructured":"Nakano K, Sadahiro T, Fujita R, Isomi M, Abe Y, Yamada Y, et al. Development of adeno-associated viral vectors targeting cardiac fibroblasts for efficient in vivo cardiac reprogramming. Stem Cell Rep. 2024;19(10):1389\u201398.","DOI":"10.1016\/j.stemcr.2024.08.002"},{"key":"4219_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101629","author":"J Hsi-Bell","year":"2025","unstructured":"Hsi-Bell J, Mietzsch M, McKenna R. The amazing AAV capsids: into the structure-verse. Mol Ther Methods Clin Dev. 2025. https:\/\/doi.org\/10.1016\/j.omtm.2025.101629.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"4219_CR118","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41587-024-02523-6","volume":"43","author":"J-J Kim","year":"2025","unstructured":"Kim J-J, Kurial SNT, Choksi PK, Nunez M, Lunow-Luke T, Bartel J, et al. AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion. Nat Biotechnol. 2025;43(12):1966\u201378. https:\/\/doi.org\/10.1038\/s41587-024-02523-6.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4219_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05059-x","volume":"9","author":"E Sen\u00eds","year":"2018","unstructured":"Sen\u00eds E, Mosteiro L, Wilkening S, Wiedtke E, Nowrouzi A, Afzal S, et al. AAV vector-mediated in vivo reprogramming into pluripotency. Nat Commun. 2018;9(1):2651. https:\/\/doi.org\/10.1038\/s41467-018-05059-x.","journal-title":"Nat Commun"},{"issue":"1","key":"4219_CR120","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03383-5","volume":"16","author":"H Noormohamadi","year":"2025","unstructured":"Noormohamadi H, Soleimani Samarkhazan H, kargar M, Maroufi F, Servatian N, Davami F. CRISPR\/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook. Discov Oncol. 2025;16(1):1530. https:\/\/doi.org\/10.1007\/s12672-025-03383-5.","journal-title":"Discov Oncol"},{"key":"4219_CR121","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W. Transdermal psoriasis treatment inspired by tumor microenvironment-mediated Immunomodulation and advanced by Exosomal engineering. J Controlled Release. 2025;382:113664. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113664.","journal-title":"J Controlled Release"},{"issue":"3","key":"4219_CR122","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.cell.2023.12.028","volume":"187","author":"T Kortemme","year":"2024","unstructured":"Kortemme T. De novo protein design-from new structures to programmable functions. Cell. 2024;187(3):526\u201344. https:\/\/doi.org\/10.1016\/j.cell.2023.12.028.","journal-title":"Cell"},{"key":"4219_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2023.1250508","volume":"3","author":"N B\u00e4ckel","year":"2023","unstructured":"B\u00e4ckel N, Hort S, Kis T, Nettleton DF, Egan JR, Jacobs JJL, et al. Elaborating the potential of artificial intelligence in automated CAR-T cell manufacturing. Front Mol Med. 2023;3:1250508. https:\/\/doi.org\/10.3389\/fmmed.2023.1250508.","journal-title":"Front Mol Med"},{"key":"4219_CR124","doi-asserted-by":"publisher","first-page":"176618","DOI":"10.1016\/j.ejphar.2024.176618","volume":"974","author":"A Boretti","year":"2024","unstructured":"Boretti A. Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review. Eur J Pharmacol. 2024;974:176618. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176618.","journal-title":"Eur J Pharmacol"},{"key":"4219_CR125","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241305856","volume":"12","author":"M Shahzadi","year":"2024","unstructured":"Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, Zokirova FR, et al. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Ther Adv Vaccines Immunother. 2024;12:25151355241305856. https:\/\/doi.org\/10.1177\/25151355241305856.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"11","key":"4219_CR126","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cels.2022.09.006","volume":"13","author":"S Lee","year":"2022","unstructured":"Lee S, Khalil AS, Wong WW. Recent progress of gene circuit designs in immune cell therapies. Cell Syst. 2022;13(11):864\u201373. https:\/\/doi.org\/10.1016\/j.cels.2022.09.006.","journal-title":"Cell Syst"},{"key":"4219_CR127","doi-asserted-by":"crossref","unstructured":"Kortemme T. De Novo protein design\u2014From new structures to programmable functions. Cell. 2024;187(3):526\u2013.","DOI":"10.1016\/j.cell.2023.12.028"},{"issue":"10","key":"4219_CR128","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","volume":"33","author":"MM Meehl","year":"2025","unstructured":"Meehl MM, Immadisetty K, Trivedi VD, Glowacki P, Prinzing B, Anido AA, et al. Computational structural optimization enhances IL13R\u03b12 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. Mol Ther. 2025;33(10):4968\u201387. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.044.","journal-title":"Mol Ther"},{"key":"4219_CR129","doi-asserted-by":"publisher","first-page":"113561","DOI":"10.1016\/j.jconrel.2025.02.057","volume":"381","author":"A Melocchi","year":"2025","unstructured":"Melocchi A, Schmittlein B, Sadhu S, Nayak S, Lares A, Uboldi M, et al. Automated manufacturing of cell therapies. J Controlled Release. 2025;381:113561. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.057.","journal-title":"J Controlled Release"},{"issue":"1","key":"4219_CR130","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/crispr.2022.0086","volume":"6","author":"G Ure\u00f1a-Bail\u00e9n","year":"2023","unstructured":"Ure\u00f1a-Bail\u00e9n G, Block M, Grandi T, Aivazidou F, Quednau J, Krenz D, et al. Automated good manufacturing practice-compatible CRISPR-Cas9 editing of hematopoietic stem and progenitor cells for clinical treatment of \u03b2-hemoglobinopathies. CRISPR J. 2023;6(1):5\u201316. https:\/\/doi.org\/10.1089\/crispr.2022.0086.","journal-title":"CRISPR J"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04219-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:33:15Z","timestamp":1772796795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4219"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04219-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (this article is a literature review).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}